Med. Pro Praxi 2009; 6(5): 243-248

Pain treatment in osteoarthritis

MUDr. Marta Olejárová CSc
Revmatologický ústav, Praha

Joint pain is the most serious symptom of osteoarthritis (OA) which needs to be paid enough attention to in the clinical practice since it

is this symptom that significantly affects the functional capacity as well as quality of life of OA patients. The pain in OA can be managed

nonpharmacologically (education, lifestyle modifications, regular exercise, physiotherapy, supportive and orthopaedic devices) or with

pharmacotherapy. Paracetamol remains the analgesic of choice; given their toxicity, nonsteroid anti-inflammatory drugs are indicated as

second-choice analgesics. Particular caution must be taken in persons with an increased gastrointestinal and cardiovascular risk, especially

in long-term treatment. Symptomatic slow acting drugs for osteoarthritis (SYSADOA) are recommended for the treatment of symptomatic

OA of grade 2 and 3 according to Kellgren-Lawrence; this treatment is associated with a slow onset of effect (weeks) which lasts even

after treatment cessation for another two to three months. SYSADOA may be combined, particularly at the beginning of the treatment

before the onset of effect, with analgesics or nonsteroid anti-inflammatory drugs. For conditions associated with inflammatory complications,

local treatment with glucocorticoid injections is appropriate; however, it may only be used up to four times a year with intervals

between two injections of at least six weeks. When conservative therapy fails, surgical treatment procedures are indicated.

Keywords: osteoarthritis, pain, nonsteroid anti-inflammatory drugs, SYSADOA.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Olejárová M. Pain treatment in osteoarthritis. Med. praxi. 2009;6(5):243-248.
Download citation

References

  1. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of the knee osteoarthritis: Report of a task force of the Standing Comittee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-1155. Go to original source... Go to PubMed...
  2. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Comittee for Internationl Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669-681. Go to original source... Go to PubMed...
  3. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, et al. Eular evidence based recommendations for the management of hand osteoarthritis - report of a task force of the Eular Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 377-388. Go to original source... Go to PubMed...
  4. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15: 981-1000. Go to original source... Go to PubMed...
  5. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidencebased, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16(2): 137-162. Go to original source... Go to PubMed...
  6. Olejárová M, Svobodová R, Jarošová H, Votavová M, Ištvánková E, Lösterová M, Pavelka K. Hodnocení účinnosti nefarmakologické léčby (pravidelné cvičení), farmakoterapie (glukosamin sulfát, GS Condro Forte(R)) a kombinace obou postupů u symptomatické gonartrózy. Výsledky otevřené, randomizované, kontrolované studie. Čes Revmatol 2008; 16: 153-160.
  7. Ravaud P, Flipo RM, Boutron I, Roy C, Mahmoudi A, Giraudeau B, et al. ARTIST (osteoarthritis intervention standardized) study of standardised consultation versus usual care for patients with osteoarthritis of the knee in primary care in France: pragmatic randomised controlled trial. BMJ 2009; 338: b421. Go to original source... Go to PubMed...
  8. Key elements for the summaries of product characteristics of non-selective NSAIDs adopted by the CHMP during its meeting in October 2005. http://www.emea.eu.int/pdfs/human/press/pr/34345605en.pdf.
  9. European Medicines Agency concludes action on COX2inhibitors. http://www.emea.eu.int/pdfs/human/press/pr/20776605en.pdf.
  10. Langford R, McKenna F, Ratcliffe S, Vojtassak J, Richarz U. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1829-1837. Go to original source... Go to PubMed...
  11. Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis 1996; 55: 829-832. Go to original source... Go to PubMed...
  12. Lo GH, LaValley M, McAlindon T, Nelson DT. Intra-articular hyaluronic acid in the treatment of knee osteoarthritis. JAMA 2003; 290: 3115-3121. Go to original source... Go to PubMed...
  13. Wang CH, Lin J, Chang CH, Lin Y, Hou S. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. J Bone Point Surg 2004; 86: 538-545. Go to original source... Go to PubMed...
  14. Modawal A, Ferrer M, Choi HK, Castle JA. Hyaluronic acid injections relieve knee pain. J Fam Pract 2005; 54: 758-767.
  15. Bellamy N, Campbell J, Robinson V, Gee T, Bourme R, Wells G. Viscosuplementation for the treatment of osteoarthritis of the knee. The Cochrane Database of Systemic Reviews 2006; 3: Art No.: CD005321.pub2. DOI 0.1002/14651858. CD005321.pub2. Go to original source... Go to PubMed...
  16. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-256. Go to original source... Go to PubMed...
  17. Pavelka K, Gatterová J, Olejárová M, Macháček S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-2123. Go to original source... Go to PubMed...
  18. Clegg D. Effects of glucosamine, chondroitin sulfate and the two in combination in painful knee osteoarthritis. New Eng J Med 2006; 354: 795-807. Go to original source... Go to PubMed...
  19. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO 3rd, Harris CL, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008; 58: 3183-3191. Go to original source... Go to PubMed...
  20. Uebelhart D, Malaise M, Marcolongo R, DeVathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004; 12: 269-276. Go to original source... Go to PubMed...
  21. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002; 21: 231-243. Go to original source... Go to PubMed...
  22. Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52: 779-786. Go to original source... Go to PubMed...
  23. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-211. Go to PubMed...
  24. Kahan A, Reginster JY, Uebelhart D, de Vathaire F, Vignon E. STOPP (Study on Osteoarthritis Progression Prevention); étude internationale, prospective, randomisée, en double insu, contrôlée contre placebo, évaluant la prévention de la progression radiologique de l´arthrose du genou pendant deux ans avec la chondroitin 4&6 sulfate. Revue Rhum 2006; 73: 2031. Go to original source...
  25. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med 2006; 166: 1899-1906. Go to original source... Go to PubMed...
  26. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a threeyear, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001; 44: 2539-2547. Go to original source...
  27. Maheu E, Mazi?res B, Valat JP, Loyau G, Le Loët X, Bourgeois P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998; 41: 81-91. Go to original source...
  28. Appelboom T, Schuermans J, Verbruggen G, Henrotin Y, Reginster JY. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 2001; 30: 242-247. Go to original source... Go to PubMed...
  29. Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2008; 16: 399-408. Go to original source... Go to PubMed...
  30. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002; 47: 50-58. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.